TAOX
TAO SynergiesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TAOX
Tao Synergies Inc.
A company dedicated to the integration of cryptocurrency encryption and artificial intelligence
1185 Avenue of the Americas, 3rd Floor , New York, New York 10036
--
TAO Synergies Inc., was incorporated in Delaware on October 31, 2012. The company is a biopharmaceutical company with product candidates in preclinical and clinical development. The Company is primarily focused on developing a product platform based on a drug candidate called Bryostatin-1, synthesized from a natural product (bryostatin) isolated from marine invertebrate organisms for the treatment of Alzheimer's disease (" AD "), which is in clinical testing.
Company Financials
EPS
TAOX has released its 2025 Q2 earnings. EPS was reported at -11.26, versus the expected 0, missing expectations. The chart below visualizes how TAOX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TAOX has released its 2025 Q3 earnings report, with revenue of 203.37K, reflecting a YoY change of NaN%, and net profit of -3.92M, showing a YoY change of 31.67%. The Sankey diagram below clearly presents TAOX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
